Transcatheter edge‐to‐edge repair for mitral regurgitation using PASCAL or MitraClip
- 26 July 2023
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (3) , 521-527
Abstract
Background: There is a paucity of data regarding the comparative efficacy and safety of Mitral valve transcatheter edge‐to‐edge repair (MTEER) using the PASCAL or MitraClip systems for patients with mitral regurgitation (MR).Methods: An electronic search was conducted for MEDLINE, COCHRANE, and EMBASE, through February 2023, for studies comparing the clinical outcomes of MTEER using PASCAL versus MitraClip systems among patients with severe MR. The primary study outcome was residual MR ≤ 2 at discharge. Data were pooled using a random‐effects model.Results: The final analysis included six studies with a total of 1581 patients, with a weighted follow‐up period of 3.5 months. Two studies only included patients with degenerative MR, while the remaining studies included both degenerative and functional MR. There was no significant difference in procedure duration between MTEER with the PASCAL or MitraClip systems. There was no difference in residual MR ≤ 2 at discharge (94.7% vs. 91.9%; odds ratio [OR]: 1.44; 95% confidence interval [CI]: 0.92–2.27) or residual MR ≤ 2 at the mid‐term follow‐up (94.6% vs. 91.0%, p = 0.05) among the PASCAL versus MitraClip systems. There was no difference between both groups in residual MR ≤ 1 at discharge (73.1% vs. 63.8%, p = 0.12), while there was greater incidence of residual MR ≤ 1 at midterm follow‐up with the PASCAL system (71.3% vs. 56.2%, p < 0.001). There was no difference between the PASCAL and MitraClip MTEER systems in technical success (97.0% vs. 97.9%, p = 0.15), procedural success (89.1% vs. 87.1%, p = 0.78), single leaflet detachment (1.8% vs. 1.4%, p = 0.55), or all‐cause mortality (3.6% vs. 4.6%, p = 0.71).Conclusion: In this meta‐analysis, we demonstrated comparable efficacy and safety between the PASCAL and MitraClip MTEER systems at short‐ and mid‐term assessments. Randomized trials are warranted to evaluate the comparative long‐term outcomes between both MTEER systems.Keywords
This publication has 15 references indexed in Scilit:
- PASCAL mitral valve repair system versus MitraClip: comparison of transcatheter edge-to-edge strategies in complex primary mitral regurgitationClinical Research in Cardiology, 2021
- 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive SummaryJACC, 2021
- Temporal Trends and Outcomes of Transcatheter Mitral Valve Repair and Surgical Mitral Valve InterventionCardiovascular Revascularization Medicine, 2020
- Conceiving MitraClip as a tool: percutaneous edge-to-edge repair in complex mitral valve anatomiesEuropean Heart Journal - Cardiovascular Imaging, 2020
- Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man studyThe Lancet, 2017
- Mitral valve disease—current management and future challengesThe Lancet, 2016
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery?European Heart Journal, 2007
- Bias in meta-analysis detected by a simple, graphical testBMJ, 1997